Finanzen von Eikon Therapeutics Inc (EIKN)EIKNEikon Therapeutics Inc

In the context of the broader market, EIKN competes directly with industry leaders such as SPRY and ASMB. With a market capitalization of $300.07M, it holds a significant position in the sector. When comparing efficiency, EIKN's gross margin of N/A stands against SPRY's 61.83% and ASMB's 100.00%. Such benchmarking helps identify whether Eikon Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Eikon Therapeutics has reported consistent net losses, with Q2 2026 showing a net income of -88,409,000. The EPS for Q2 2026 was -1.63, which is worse than the expected -1.61, indicating financial instability. The current ratio has been fluctuating, but it was 9.89 in Q2 2026, suggesting some liquidity.